MedTrace Logo

Fruquintinib in the Treatment of Soft Tissue Sarcoma

NCT05142631 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-03-02

No results posted yet for this study

Summary

To evaluate the efficacy of Fruquintinib in patients with chemotherapy insensitive or chemotherapy resistant soft tissue sarcoma

Conditions

  • Soft Tissue Sarcoma

Interventions

DRUG

Fruquintinib

To observe the efficacy and safety of Fruquintinib in the first-line treatment of desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or second-line and posterior line treatment of angiosarcoma.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xiaowei Zhang, Doctor · Fudan Cancer Center，Shanghai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-21
Primary Completion
2023-05-30
Completion
2023-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05142631 on ClinicalTrials.gov